RLCO Profits Grow by Double Digits
PT Abadi Lestari Indonesia Tbk (RLCO) has recorded double-digit net profit growth in the first half of 2026 amidst market dynamics. As of 30 June 2026, the company reported net profit attributable to the owners of the parent entity of Rp 20.36 billion, an increase of 13.39% compared to Rp 17.96 billion during the same period the previous year.
The President Director of PT Abadi Lestari Indonesia Tbk, Edwin Pranata, stated that this achievement reflects the company’s ability to maintain business performance, strengthen financial fundamentals, and continue sustainable business development. He expressed gratitude for closing the first semester of 2026 with positive performance, noting that this serves as motivation to enhance competitiveness through operational quality, product innovation, and healthy business management.
Throughout the first half of 2026, the company recorded sales of Rp 272 billion, with processed edible bird’s nest products remaining the primary revenue contributor. Sales of processed edible bird’s nest products were recorded at Rp 234.3 billion, or approximately 86.2% of total sales, while consumer products contributed Rp 37.6 billion, or about 13.8%.
In line with increased business activity, the cost of goods sold was recorded at Rp 210.9 billion, resulting in a gross profit of Rp 61.09 billion. Regarding its financial position, the company’s total assets increased by 3.22% to Rp 835.8 billion as of 30 June 2026, compared to Rp 809.7 billion on 31 December 2025, primarily driven by an increase in current assets to Rp 730.28 billion.
Total liabilities were recorded at Rp 510.1 billion, a slight increase from the end of 2025. Conversely, long-term liabilities decreased to Rp 21.3 billion from the previous Rp 27.6 billion, while total equity increased by 6.67% to Rp 325.7 billion, supported by the current period’s profit. From a liquidity perspective, cash receipts from customers increased to Rp 221.9 billion compared to Rp 200.1 billion in the first half of 2025. Investment activities during the period focused on supporting business development, including investments in intangible assets. As of 30 June 2026, intangible assets under development largely consist of the bioactive testing development for phytopharmaceutical products, which is approximately 32% financially complete and expected to be finished in 2027. With prudent financial management, the company closed the first half of 2026 with cash and cash equivalents of Rp 65.7 billion, which remains adequate to support operational needs and business expansion.